

Επιστημονική Εταιρεία «Καρκίνος: Εκπαίδευση Ερεύνα & Κλινική Πράξη»

Σε συνεργασία: Ελληνική Εταιρεία Νευροενδοκρινών Όγκων Ιατρική Εταιρεία Έρευνας και Εκπαίδευσης Α΄ Παθολονική-Ονκολονική Κλινική, Γ.Α.Ο.Ν.Α. «Ο Άνιος Σάββας» • Παθολογική-Ογκολογική Κλινική, Ε.Α.Ν.Π. «Μεταξά» Ομάδα Νέων Ελλήνων Ογκολόγων (ONEO)

21°s aiúvas:

από την ανθοφορία στη συγκομίδή

ΣΥΝΕΔΡΙΟ Από τη Χημειοθεραπεία στη Μοριακή

Υπό την αιγίδα:

Χορηγούνται 15 Μόρια Συνεχιζόμενης Ιατρικής Εκπαίδευσης (CME-CPD)



Athens



αντι-αγγειογενετικοί παράγοντες & ακτινοθεραπεία

Ιωάννης Γεωργακόπουλος MD, PhD Ακτινοθεραπευτής Ογκολόγος

- more than half of cancer pts undergo RT at some stage during their treatment
 - curative intent
 - palliative

 improved clinical benefit of radiotherapy understanding radiobiology technical advancements

technical advancements

intensity modulated radiation therapy (IMRT)
volumetric modulated arc therapy (VMAT)
image guided radiation therapy (IGRT)
respiratory gated radiation therapy
proton beam therapy



- hypofractionated radiotherapy
- stereotactic radiotherapy

understanding radiobiology

5 + 1 R's of radiotherapy:

Repair: by applying fractionated RT, normal cells have the opportunity to repair sublethal DNA damage between each fraction while cancer cells are unable to sufficiently repair DNA damage due to defective or suppressed repair pathways

Redistribution: Fractionated RT increases the chance that cells that were in a radioresistant phase

Repopulation: the increase in cell division that is seen in normal and cancer cells after


Radiosensitivity refers to the intrinsic radiosensitivity or radioresistance of different cell types


Reoxygenation is related to the dynamic and changing hypoxic status of tumor tissue. Fractionated RT increases the chance that all areas of the tumor tissue receive a dose of irradiation when oxygenation is improved

Reactivation of the anti-tumor immune response

angiogenesis and cancer therapy

tumor angiogenesis





Bevacizumab	Humanized monoclonal anti-VEGF-A antibody
Ziv-aflibercept	Fusion protein against VEGF-A, VEGF-B and PIGF
Sorafenib	Multi-tyrosine kinase inhibitor
Sunitinib	Multi-tyrosine kinase inhibitors
Axitinib	Receptor tyrosine kinase inhibitor
Nintedanib	Receptor tyrosine kinase inhibitor
Regorafenib	Receptor tyrosine kinase inhibitor
Pazobanib	Receptor tyrosine kinase inhibitor
Cabozantinib	Receptor tyrosine kinase inhibitor
Vandetanib	Receptor tyrosine kinase inhibitor
Thalidomide	Inhibitor of Akt phosphorylation

radiotherapy and hypoxia